RecallDepth
Class II Ongoing

Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 NDC 59651-145-30

This recall is currently active, issued December 4, 2019. It was issued by Auromedics Pharma Llc.

Company
Auromedics Pharma Llc
Recall Initiated
November 6, 2019
Posted
December 4, 2019
Recall Number
D-0528-2020
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
134,160 bottles
Firm Location
East Windsor, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.

Distribution

nationwide

Lot / Code Info

RA3018001-A Jul 2020 RA3018002-A Jul-2020 RA3018003-A Jul 2020 RA3018004-A Aug 2020 RA3018005-A Aug 2020 RA3018006-A Aug 2020 RA3018007-A Sep 2020 RA3018008-A Sep 2020 RA3018009-A Sep 2020 RA3018010-A Oct 2020 RA3019001-A Jan 2021 RA3019002-A Jan 2021 RA3019003-A May 2021

More recalls by Auromedics Pharma Llc

View all recalls by this company →

Other recent Class II Drug recalls